In clinical practice, patients with breast cancer exhibiting high Ki‐67 expression typically necessitate conventional chemotherapy, whereas those displaying low Ki‐67 expression may primarily benefit from surgical intervention and endocrine therapy. This evidence concerns the gene MKI67 and breast cancer.